Jesus Lovera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jesus Lovera has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Deidre Devier
Department of Neurology, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Department of Cell Biology and Anatomy, Louisiana State University Health Sciences Center, New Orleans, LA, USA
4 shared publications - Alexander B. Ramos
Louisiana State University Health Sciences Center, New Orleans, LA, USA
2 shared publications - Brain Copeland
Louisiana State University Health Sciences Center - New Orleans, United States
2 shared publications - Morganne Manuel
Medical College of Georgia - Augusta University, United States
2 shared publications Olinda Verdecie Feria
Louisiana State University Health Sciences (LSUHSC) Center
2 shared publications- Shannin Moody
Louisiana State University Health Sciences Center - New Orleans, United States
2 shared publications
Latest Publications
- Open Access
- 17 September 2025
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 13, 100395
A single Center study of the Symbol Digit Modalities test as a screening tool for cognitive impairment in Parkinson’s disease
- 17 September 2025
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 13, 100395
Open AccessA single Center study of the Symbol Digit Modalities test as a screening tool for cognitive impairment in Parkinson’s disease
- 26 September 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 466, 123260
The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis
- 26 September 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 466, 123260
The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis
- 1 January 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 420, 117202
A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways
- 1 January 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 420, 117202
A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways
- 25 December 2020
- Published by Springer Nature
- p. 415-435
Infectious Diseases of the Hypothalamic-Pituitary Axis
- 25 December 2020
- Published by Springer Nature
- p. 415-435
Infectious Diseases of the Hypothalamic-Pituitary Axis
- 25 December 2020
- Published by Springer Nature
- p. 437-478
Inflammatory Conditions of the Hypothalamus
- 1 October 2020
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 197, 106173
Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization
- 1 October 2020
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 197, 106173
Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization
- Open Access
- 1 November 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 358 (1-2) , 46-52
Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies
- 1 November 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 358 (1-2) , 46-52
Open AccessPolyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies
- 1 September 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 344 (1-2) , 1-2
Tumefactive multiple sclerosis and fingolimod
- 1 September 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 344 (1-2) , 1-2
Tumefactive multiple sclerosis and fingolimod
- 9 October 2013
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 13 (11) , 1-5
Stress in Multiple Sclerosis: Review of New Developments and Future Directions
In the experimental autoimmune encephalitis model of multiple sclerosis, the effects of stress on disease severity depend on multiple factors, including the animal’s genetics and the type of stressor. The studies in humans relating stress to the risk of developing multiple sclerosis have found discordant results. The studies looking at the association of stress with relapses show a fairly consistent association, where higher stress is associated with a higher risk of relapse. Higher stress levels also appear to increase the risk of development of gadolinium-enhancing lesions. A recent randomized trial shows that reducing stress using stress management therapy (SMT), a cognitive–behavioral therapy approach, results in a statistically significant reduction in new magnetic resonance imaging lesions. The magnitude of this effect is large and comparable to the effects of existent disease-modifying therapies, but no data exist yet proving that SMT reduces relapses or clinical progression; the effect of SMT appears to be short-lived. Additional work is needed to improve the duration of this effect and make this therapy more widely accessible.
- 9 October 2013
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 13 (11) , 1-5
Stress in Multiple Sclerosis: Review of New Developments and Future Directions
In the experimental autoimmune encephalitis model of multiple sclerosis, the effects of stress on disease severity depend on multiple factors, including the animal’s genetics and the type of stressor. The studies in humans relating stress to the risk of developing multiple sclerosis have found discordant results. The studies looking at the association of stress with relapses show a fairly consistent association, where higher stress is associated with a higher risk of relapse. Higher stress levels also appear to increase the risk of development of gadolinium-enhancing lesions. A recent randomized trial shows that reducing stress using stress management therapy (SMT), a cognitive–behavioral therapy approach, results in a statistically significant reduction in new magnetic resonance imaging lesions. The magnitude of this effect is large and comparable to the effects of existent disease-modifying therapies, but no data exist yet proving that SMT reduces relapses or clinical progression; the effect of SMT appears to be short-lived. Additional work is needed to improve the duration of this effect and make this therapy more widely accessible.